Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients

Table 1 Association between circulating tumor cell (CTC) status by AdnaTest or by CTC-specific signature and the clinico-pathological features in breast cancers patients

			AdnaTest	AdnaTest+		AdnaTest-			5-gene panel	5-gene panel+	5-gene panel-
Variable	N	%	N (evaluable)	N	%	N	%	p-value	N (evaluable)	N	%	N	%	p-value
All patients	51	100.0	46	18	39.1	28	60.9		49	37	75.5	12	24.5
Age (years)
<50	11	21.6	10	5	50.0	5	50.0	.4802^a	10	9	90.0	1	10.0	.4143^a
≥50	40	78.4	36	13	36.1	23	63.9	.4802^a	39	28	71.8	11	28.2	.4143^a
Clinical stage
M0	20	39.2	17	5	29.4	12	70.6	.3011^b	20	13	65.0	7	35.0	.1890^a
M+	31	60.8	29	13	44.8	16	55.2	.3011^b	29	24	82.8	5	17.2	.1890^a
ER and PgR status
Positive for either	44	86.3	39	13	33.3	26	66.7	.0929^a	42	31	73.8	11	26.2	.6651^a
Negative for both	7	13.7	7	5	71.4	2	28.6	.0929^a	7	6	85.7	1	14.3	.6651^a
HER2/neu status
Positive	9	17.6	8	6	75.0	2	25.0	.0424^a	9	6	66.7	3	33.3	.6693^a
Negative	42	82.4	38	12	31.6	26	68.4	.0424^a	40	31	77.5	9	22.5	.6693^a
Subtype
Luminal	40	78.4	36	11	30.6	25	69.4	.0646 ^a .0332^c	38	29	76.3	9	23.7	.4808 ^a 1^c
Her2+	8	15.7	7	5	71.4	2	28.6		8	5	62.5	3	37.5
Triple-negative	3	5.9	3	2	66.7	1	33.3		3	3	100.0	0	0.0
Histotype
Ductal	34	66.7	32	13	40.6	19	59.4	.7366^a,d	33	26	78.8	7	21.2	.7098^a,d
Others	15	29.4	13	4	30.8	9	69.2	.7366^a,d	14	10	71.4	4	28.6	.7098^a,d
Unknown	2	3.9	1	1	100.0	0	0.0		2	1	50.0	1	50.0
Tumor grade
G1 or G2	24	47.1	21	7	33.3	14	66.7	.5671^b,d	22	17	77.3	5	22.7	1^a,d
G3	20	39.2	19	8	42.1	11	57.9	.5671^b,d	20	16	80.0	4	20.0	1^a,d
Unknown	7	13.7	6	3	50.0	3	50.0		7	4	57.1	3	42.9
Ki67
<10 %	5	9.8	4	2	50.0	2	50.0	.5840^a,d	5	4	80.0	1	20.0	.6431^a,d
≥10%	30	58.8	26	8	30.8	18	69.2	.5840^a,d	28	18	64.3	10	35.7	.6431^a,d
Unknown	16	31.4	16	8	50.0	8	50.0		16	15	93.75	1	6.25

ISSN: 1756-9966